Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
Supreme Court Tests Federal Reserve Independence Amid Trump’s Bid to Fire Lisa Cook 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Minnesota Judge Rejects Bid to Halt Trump Immigration Enforcement in Minneapolis 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
